Merck & Co. Inc. (MRK)

62.51
0.00 (0.00)
NYSE : Health Technology
Prev Close 62.51
Day Low/High 62.01 / 62.54
52 Wk Low/High 52.83 / 66.41
Avg Volume 9.64M
Exchange NYSE
Shares Outstanding 2.69B
Market Cap 168.17B
EPS 0.90
P/E Ratio 71.85
Div & Yield 1.92 (3.03%)

Latest News

Four Great, Conservative Income Stocks

From Coca-Cola to Pfizer, these blue chips offer well-supported dividend payouts.

3 Pharma Stocks Goldman Sachs Sees as Buys

3 Pharma Stocks Goldman Sachs Sees as Buys

The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Advanced Hepatocellular Carcinoma

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Advanced Hepatocellular Carcinoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

General Electric's Stock Is Attractive for the First Time in 2 Years: Jim Cramer

General Electric's Stock Is Attractive for the First Time in 2 Years: Jim Cramer

Jim Cramer says earnings could break the tie between the bulls and the bears -- unless China blinks. Here's the game plan for next week.

The New #22 Most Shorted Dow Component: Merck

The New #22 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 06/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Merck To Present New Data From Studies Of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, At AIDS 2018

Merck To Present New Data From Studies Of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, At AIDS 2018

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from the company are scheduled to be presented at the 22nd International AIDS Conference (AIDS 2018) taking place July 23-27 in Amsterdam.

LYNPARZA® (olaparib) Approved In Japan For BRCA-Mutated Metastatic Breast Cancer

LYNPARZA® (olaparib) Approved In Japan For BRCA-Mutated Metastatic Breast Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA ® (olaparib) tablets for use in patients with unresectable or...

Merck Announces Findings From WHO-led Study Of Investigational Heat-Stable Carbetocin For Preventing Excessive Bleeding After Childbirth

Merck Announces Findings From WHO-led Study Of Investigational Heat-Stable Carbetocin For Preventing Excessive Bleeding After Childbirth

Merck (NYSE: MRK), known as MSD outside the United States and Canada, through its Merck for Mothers initiative announced study results on an investigational heat-stable formulation of carbetocin for the prevention of excessive bleeding after childbirth,...

REPEAT/LYNPARZA® (olaparib) Significantly Delays Disease Progression In Phase 3 First-Line SOLO-1 Trial For Ovarian Cancer

REPEAT/LYNPARZA® (olaparib) Significantly Delays Disease Progression In Phase 3 First-Line SOLO-1 Trial For Ovarian Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the randomized, double-blinded, placebo-controlled, Phase 3 SOLO-1 trial of LYNPARZA ® (olaparib) tablets.

Merck To Hold Second-Quarter 2018 Sales And Earnings Conference Call On July 27

Merck To Hold Second-Quarter 2018 Sales And Earnings Conference Call On July 27

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.

LYNPARZA® (olaparib) Significantly Delays Disease Progression In Phase 3 First-Line SOLO-1 Trial For Ovarian Cancer

LYNPARZA® (olaparib) Significantly Delays Disease Progression In Phase 3 First-Line SOLO-1 Trial For Ovarian Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the randomized, double-blinded, placebo-controlled, Phase 3 SOLO-1 trial of LYNPARZA ® (olaparib) tablets.

FDA Accepts Supplemental Biologics License Application For Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy In Advanced Melanoma

FDA Accepts Supplemental Biologics License Application For Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy In Advanced Melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Merck Presents New Data From The Comparative Trials With Sitagliptin (CompoSIT) Clinical Trial Program With JANUVIA® (sitagliptin)

Merck Presents New Data From The Comparative Trials With Sitagliptin (CompoSIT) Clinical Trial Program With JANUVIA® (sitagliptin)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from the Comparative Trials with Sitagliptin (CompoSIT) clinical trials with JANUVIA ® (sitagliptin).

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Jim Cramer says many stocks already reflect the worst-case scenarios, and that means he sees a lot of upside potential.

Novo Nordisk Stock Rises 4% Over 2 Sessions

Novo Nordisk Stock Rises 4% Over 2 Sessions

Pharma firm's new diabetes drug showed positive test results.

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For Treatment Of Refractory Or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For Treatment Of Refractory Or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #8 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #91 spot out of 500.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AINV, CRNT, JCAP, MRK, ODC Downgrades: FRPH, SSY, UHS Initiations: JE Read on to get TheStreet Quant Ratings' detailed report:

Merck KGaA, Darmstadt, Germany Provides Update On Tepotinib Phase II Results In Advanced Hepatocellular Carcinoma

Merck KGaA, Darmstadt, Germany Provides Update On Tepotinib Phase II Results In Advanced Hepatocellular Carcinoma

DARMSTADT, Germany, June 11, 2018 /PRNewswire/ -- Not intended for UK-based media    Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib,  as a monotherapy  in  MET-positive, advanced hepatocellular carcinoma (HCC)...

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

I continue to see these names as bargains in the biotech and biopharma space.

Small Cap Biotech Bargains

Small Cap Biotech Bargains

Here are 2 small caps I continue to see as bargains in this space.

Sanofi, Merck and J&J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

Jim Cramer: Tech Can't Do it All Alone

Jim Cramer: Tech Can't Do it All Alone

Tech and retail gains aren't enough to lead markets to new highs.

TheStreet Quant Rating: B- (Buy)